Dentsply executive shift
This article was originally published in The Gray Sheet
President and COO Gary Kunkle, Jr. will replace retiring John Miles II as CEO on Jan. 1, 2004. Miles, an 18-year Dentsply vet, will stay on as chair. Executive VP Thomas Whiting will fill the positions served by Kunkle, who joined the firm in 1997 after serving as president of J&J's Vistakon and Orthopaedics divisions...
You may also be interested in...
Danaher Corp.'s $102.5 mil. cash purchase of Dentsply's Gendex dental imaging division will enable the firm to leverage a broader industry shift from analog to digital technology, the firm says
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.